COCHLEAR MEDICAL DEVICE COMPANY INDIA PRIVATE LIMITED

PolyActiva Secures $40M Series C to Advance Revolutionary Glaucoma Implant Technology

- Melbourne-based PolyActiva raised $40 million in Series C funding, including $27 million from Australia's National Reconstruction Fund, to advance its biodegradable glaucoma treatment implant. - The company's innovative two-millimeter polymer implant delivers medication directly into the eye over six months, potentially eliminating daily eye drops for glaucoma patients. - With Phase 2B clinical trials underway, PolyActiva aims to commercialize the technology by 2029 while maintaining its Australian headquarters and expanding local manufacturing capabilities. - The funding addresses a critical need for the 80 million people globally affected by glaucoma, a number expected to reach 111 million by 2040.